Mokari Atabak's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Jul 17, 2026
- Accession no.
- 0001193125-26-308058
- Filed
- Jul 17, 2026, 6:31 PM ET
- Trade date
- Jul 15, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $3.51M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mokari AtabakCIK 0001678419 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 15, 2026 | Common Stock | MOption exerciseAcquired | +15,833 | $19.26 | +$304,943.58 | 31,963 | Direct | |
| Jul 15, 2026 | Common Stock | MOption exerciseAcquired | +24,167 | $23.06 | +$557,291.02 | 56,130 | Direct | |
| Jul 15, 2026 | Common Stock | SSaleDisposed | −7,919 | $86.78F3 | −$687,179.14 | 48,211 | Direct | |
| Jul 15, 2026 | Common Stock | SSaleDisposed | −28,460 | $87.89F4 | −$2,501,244.1 | 19,751 | Direct | |
| Jul 15, 2026 | Common Stock | SSaleDisposed | −3,520 | $88.30F5 | −$310,821.63 | 16,231 | Direct | |
| Jul 15, 2026 | Common Stock | SSaleDisposed | −101 | $89.43F6 | −$9,032.25 | 16,130 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 15, 2026 | Common Stock | MOption exerciseDisposed | −15,833 | $0.00 | $0 | 4,167 | Direct | |
| Jul 15, 2026 | Common Stock | MOption exerciseDisposed | −24,167 | $0.00 | $0 | 175,833 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $86.20 to $87.19 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $87.23 to $88.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F5
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $88.24 to $89.07 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F6
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $89.25 to $89.43 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
The power of attorney under which this form was signed is on file with the Commission.